NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors
NCT05583201 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 18
Last updated 2023-02-08
Summary
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D/CLDN18.2-based CAR-T cells infusion in the treatment of advanced NKG2DL+/CLDN18.2+ solid tumors.
Conditions
Interventions
- BIOLOGICAL
-
KD-496
Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells
Sponsors & Collaborators
-
KAEDI
collaborator OTHER -
jianming xu
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-10-13
- Primary Completion
- 2024-06-01
- Completion
- 2026-06-01
Countries
- China
Study Locations
More Related Trials
-
Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours
NCT03415100 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of RD14-01 in Patients With Advanced Solid Tumors
NCT05748938 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors
NCT05564858 ·Status: RECRUITING ·Phase: PHASE1
-
Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer
NCT04199559 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment
NCT06095934 ·Status: RECRUITING ·Phase: NA
-
Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors
NCT02843204 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
NCT03356782 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer
NCT07298200 ·Status: RECRUITING ·Phase: PHASE1
-
Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor
NCT04864821 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors
NCT05944185 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor
NCT06166472 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma
NCT03890198 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors
NCT06728189 ·Status: RECRUITING ·Phase: PHASE1
-
Combination Immunotherapy Targeting Sarcomas
NCT04433221 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
NCT04503980 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients
NCT06284226 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors
NCT06084286 ·Status: RECRUITING ·Phase: PHASE1
-
Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma
NCT03930498 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
NCT05798546 ·Status: UNKNOWN ·Phase: PHASE1
-
A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors
NCT06773091 ·Status: RECRUITING ·Phase: PHASE1
-
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
NCT05420545 ·Status: UNKNOWN ·Phase: PHASE1
-
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
NCT03093688 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
NCT06394622 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of GC203 TIL in Advanced Solid Tumors (NF)
NCT07256756 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma
NCT05275062 ·Status: UNKNOWN ·Phase: EARLY_PHASE1